New pill for weight loss enters human testing

NCT ID NCT06562907

Recruiting now Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new oral drug called GS-4571 in healthy people, non-diabetic obese individuals, and non-obese people with type 2 diabetes. The main goals are to see how the drug moves through the body, how safe it is, and how food or acid-reducing drugs affect it. About 134 participants will take single or multiple doses, with some receiving a placebo. This is a safety and dosing trial, not yet testing if the drug works for weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GS-4571 (oral drug)
What this could lead to: If successful, this could lead to a new oral medication for weight management, potentially helping with obesity and type 2 diabetes.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not effectiveness. The drug may not work or could have side effects. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WEIGHT MANAGEMENT

Contacts and locations

Locations

ICON
RECRUITING

Salt Lake City, Utah, 84124, United States
ICON Early Phase Services, LLC
RECRUITING

San Antonio, Texas, 78232, United States
Qps-Mra, Llc.
RECRUITING

Miami, Florida, 33143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.